Key takeaways
Clinical trial data shows that people without diabetes taking tirzepatide lost an average of 15%–21% of their body weight, depending on dose, over 72 weeks. (People with diabetes lost an average of 13%–15% of their body weight over a similar timeframe.)
Most people begin losing noticeable weight within the first 5–12 weeks of treatment, with the most significant results coming between months three and 12 though results may vary.
Paying attention to your overall nutrition and staying physically active can help protect muscle mass while you’re on tirzepatide. A balanced, nutrient-dense diet and regular exercise can support healthier weight loss and help your body lose more fat than muscle.
Stopping tirzepatide can lead to weight regain. Data shows that most people who discontinue the medication regain at least 25% of the weight they had lost within a year.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Clinical trial data shows that people without diabetes taking tirzepatide lost an average of 15%–21% of their body weight, depending on dose, over 72 weeks. (People with diabetes lost an average of 13%–15% of their body weight over a similar timeframe.)
Most people begin losing noticeable weight within the first 5–12 weeks of treatment, with the most significant results coming between months three and 12 though results may vary.
Paying attention to your overall nutrition and staying physically active can help protect muscle mass while you’re on tirzepatide. A balanced, nutrient-dense diet and regular exercise can support healthier weight loss and help your body lose more fat than muscle.
Stopping tirzepatide can lead to weight regain. Data shows that most people who discontinue the medication regain at least 25% of the weight they had lost within a year.
How much weight can you lose on tirzepatide? This is a common question, and the short answer is: a lot. More than most other medications currently available.
But how much weight you lose and how fast you lose it depends on several factors, including your dose, your habits, and how long you stay on the medication. Here's what the research actually shows.
How much weight can you lose on tirzepatide?
Tirzepatide weight loss averages about 15%–21% of body weight reduction, depending on the dose, over 72 weeks (about 17 months) for those without type 2 diabetes.
For context, someone starting at 230 lbs (104 kg) could expect to lose around 34–48 lbs over that time period.
These results come from SURMOUNT-1, a large clinical trial that enrolled 2,539 adults with obesity (body mass index, or BMI, of 30 or greater) or overweight (BMI of at least 27) and at least one weight-related health condition. Participants did not have type 2 diabetes.
All participants also followed a reduced-calorie diet and got at least 150 minutes of physical activity per week while taking the medication.
If you have diabetes, don’t worry. You can still lose weight with tirzepatide. The SURMOUNT-2 trial of people with type 2 diabetes showed an average weight loss of 13%–15% over 72 weeks.
In people with and without diabetes, tirzepatide produced far greater weight loss than the placebo, which resulted in only a 3% reduction over the same period.
How tirzepatide helps you lose weight
Tirzepatide works by activating two hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). By targeting both receptors, tirzepatide produces a more powerful effect than medications that only target one.
Here's what tirzepatide actually does in your body:
In your brain, tirzepatide reduces hunger and food cravings while increasing feelings of fullness. This makes it easier to eat less without feeling like you're fighting yourself every meal.
In your stomach, it slows digestion, so food moves through more gradually. This keeps you feeling satisfied for longer after eating.
In your pancreas, it improves insulin production and lowers glucagon, a hormone that raises blood sugar.
In your fat tissue, tirzepatide improves how your body uses and stores fat. It also raises adiponectin in people with type 2 diabetes, a hormone that helps regulate metabolism.
In fat cells, it works with insulin to improve glucose and lipid uptake after meals, while promoting fat breakdown and fat burning during fasting.
In the liver, it reduces liver fat, helping improve metabolic health.
Throughout the body, it decreases both visceral fat (around your organs) and subcutaneous (under-the-skin) fat. These changes support better overall metabolic health.
Tirzepatide’s dual GIP/GLP-1 activity, with its far-reaching effects across the body, is what makes it different from other weight loss medications.
What to expect at each dose of tirzepatide
Tirzepatide is available in five dosage strengths, ranging from 2.5 mg to 15 mg weekly.
It has three recommended maintenance doses: 5 mg, 10 mg, and 15 mg. Treatment typically starts at a lower dose of 2.5 mg weekly and is gradually increased over several weeks, based on your response to the medication and tolerance of side effects.
In SURMOUNT-1 trial, weight loss increased with higher doses. While results vary, here's what the study participants achieved at 72 weeks:
5 mg/week: Participants lost an average of about 15% (35 lbs). About 85% of people in this group lost at least 5% of body weight, and 15% lost 25% or more.
10 mg/week: Participants lost an average of 19.5% of their body weight. Based on the study’s average starting weight of 231 lbs, this translates to 45 lbs. Around 89% lost at least 5%, and 50% lost 20% or more.
15 mg/week: Participants lost an average of 20.9% of their body weight, or 48 lbs. Roughly 91% lost at least 5%, 57% lost 20% or more, and 36% lost 25% or more. For some participants, this approaches the results typically seen with bariatric surgery (usually 25%–30%).
In SURMOUNT-2, participants also experienced increasing weight loss with each dosage. That being said, they lost slightly lower percentages of their body weight at each dosage than people without type 2 diabetes.
How long does it take to lose weight on tirzepatide? Your weight loss timeline
So, how fast do you lose weight on tirzepatide? It’s important to know that results won’t happen all at once, and they look different for everyone. Here's what clinical data suggests you can expect at each phase.
Weeks 1–4: adjustment period
During this phase, you're taking the starting dose of 2.5 mg. Most people don't see dramatic weight changes yet. Your system is getting used to the medication, and your dose is still at its lowest.
Some people may experience nausea or digestive changes as their body adjusts. These side effects are most common during dose escalation and typically improve over time.
Weeks 5–12: noticeable loss begins
Across BMI categories, participants saw similar reductions in the first 12 weeks. After about 24 weeks, patterns began to separate, with some groups continuing to lose weight for longer before eventually reaching a plateau.
Higher doses (10 mg and 15 mg) were associated with a longer time before reaching that plateau. Meaning, people on those doses tended to continue losing weight for a longer period.
Months 3–6: steady progress
By this point, most people are approaching or have reached their maintenance dose. Weight loss typically continues steadily. SURMOUNT-1 trial data shows significant reductions were already measurable by week 24, long before the 72-week end.
Months 6–12: approaching maximum results
About 88%–90% of participants had reached a weight plateau by week 72, meaning their weight had stabilized and was no longer decreasing significantly.
People taking 10 mg or 15 mg tended to reach that plateau later than those on 5 mg. Higher doses were associated with a longer active weight-loss phase and greater overall weight reduction, even though by week 72, the majority of participants had reached a plateau.
5 factors that determine how much weight you'll lose
If you’re taking tirzepatide for weight loss, keep in mind that the numbers on the scale are influenced by a few factors:
1. Starting weight
Tirzepatide results are measured as a percentage of your starting weight, which means the more you weigh at the start, the more pounds that percentage represents.
For example, someone starting at 280 lbs who loses 15% would lose 42 lbs. Someone starting at 180 lbs, losing the same 15%, would lose 27 lbs. That’s the same medication, same effort, different numbers on the scale, and both with meaningful results.
2. Dosage
Tirzepatide is started at a low dose of 2.5 mg and usually increases by 2.5 mg every four weeks during the first 20 weeks, giving your body time to adjust before reaching a maintenance dose.
Higher doses generally produce greater weight loss. In the SURMOUNT-1 trial, 50% of participants taking 10 mg and 57% taking 15 mg lost 20% or more of their body weight by week 72.
Your healthcare provider will usually increase your dose gradually over about 20 weeks, typically once every four weeks, to give your body time to adjust.
Since higher doses have been linked to greater average weight loss in clinical trials, your provider may aim for a higher dose, but the right maintenance dose for you will depend on how well you respond to and tolerate the medication.
3. Nutrition and calorie intake
Tirzepatide helps many people eat less. Weight loss comes down to a calorie deficit, meaning you consistently take in fewer calories than your body uses. In the SURMOUNT-1 trial, participants followed a reduced-calorie diet alongside the medication.
Because people often feel less hungry on tirzepatide, it’s possible to eat much less overall. That can help with weight loss, but it also means you need to be intentional about food quality and choices.
Choose nutrient-dense options, such as fruits, vegetables, whole grains, legumes, lean proteins, nuts, and seeds, to help your body get the vitamins, minerals, fiber, and protein it needs.
Protein is particularly important during weight loss. When calories drop, the body can lose muscle along with fat. Eating enough protein can support muscle maintenance through this phase.
Find your recommended calorie deficit
A calorie deficit happens when you consume fewer calories than you burn. It’s key to weight loss and can help guide your nutrition strategy. Use the tool below to estimate how many calories you need each day to reach your weight loss goals safely.
Maintain your current weight
----
cal daily
Lose one pound per week
----
cal daily
Time to achieve your __ goal weight
----
Weeks
This calculator is for informational purposes only and not a substitute for medical advice. Individual needs vary. Consult a healthcare provider before making changes. Eating fewer than 1,200 (women) or 1,500 (men) calories a day is not recommended.
4. Physical activity and exercise
Exercise supports weight loss and long-term weight maintenance. In clinical trials, participants aimed for at least 150 minutes of physical activity per week.
Cardio activities like walking, cycling, or swimming help increase calorie burn and improve heart health. Strength or resistance training supports muscle mass. Even moderate, consistent movement can make a difference.
Combining medication with regular physical activity and balanced nutrition gives you the best chance of achieving steady, sustainable tirzepatide weight loss results.
5. Adherence to weekly injections
Tirzepatide is a once-weekly injection, and consistency matters. Missing doses or taking the medication irregularly can disrupt the steady hormone levels that drive its effect.
Sticking to a consistent day and time each week can make it easier to remember your dose.
Why weight plateaus happen (and what they mean)
If your weight loss slows down or stalls at some point, don't worry. This happens to plenty of people on tirzepatide, and it doesn't mean the medication has stopped working.
An analysis of trials found that by week 72, about 88%–90% of participants had reached a weight loss plateau. This is one of the most common parts of the weight loss journey, and it's completely normal.
How soon a plateau hits varies from person to person. People who started with a higher BMI tended to have a longer active weight loss phase.
In the SURMOUNT-1 trial, people with obesity continued losing weight for a median of about nine months before reaching a plateau, compared to about six months for those who started in the overweight category.
Those taking higher doses (10 mg or 15 mg) as well as those who were younger or biologically female also tended to reach a plateau later.
Think of a plateau less as hitting a wall and more as your body settling into its new normal. It’s a good idea to be consistent, keep up with your weekly injections, focus on protein-rich foods, stay active, and check in with your healthcare provider if you have concerns.
How Ro makes weight loss with GLP-1 medications easier
Starting a weight loss medication is a big step, and having the right support behind you makes a real difference.
Ro makes it easy to find out if you qualify for prescription weight loss treatment, including medications like Zepbound (tirzepatide), Wegovy (semaglutide), and Ozempic (semaglutide).
Here's how it works:
1. Answer a few questions online. Tell Ro about your health history and goals. You'll typically find out if you're eligible within about two days.
2. A licensed provider reviews your information. If you qualify, they'll prescribe the right treatment for you. With insurance, most people get started within 2–3 weeks; without insurance, often sooner.
3. Ro handles the insurance paperwork. If you're covered, your prescription goes to your pharmacy. If not, Ro will appeal on your behalf or help you explore alternatives.
4. Your medication arrives. If prescribed, it can be shipped directly to your home or made available for pickup at your preferred pharmacy.
5. Get ongoing support for as long as you need it. You'll have access to your care team throughout treatment, with regular check-ins to help you stay consistent and on track.
Is tirzepatide right for you?
Tirzepatide is approved to:
Treat type 2 diabetes (Mounjaro)
Reduce weight and maintain long-term weight loss in adults with obesity or overweight and a weight-related disease (Zepbound)
Treat moderate to severe obstructive sleep apnea in adults with obesity (Zepbound)
Because it leads to significant weight loss, some healthcare providers prescribe Mounjaro (tirzepatide drug approved for diabetes) off-label for people with obesity but without additional weight-related conditions.
In large weight loss studies, most participants had obesity to begin with. The average BMI was 38, and nearly 95% had a BMI of 30 or higher.
That means the results we talk about mainly apply to people who meet clinical criteria for overweight or obesity, not those at lower weights.
A few things to consider going in:
Results vary from person to person, and while the clinical trial data is impressive, it doesn’t guarantee that you’ll see those exact numbers in real-world settings.
Insurance coverage for tirzepatide for weight loss varies significantly, and out-of-pocket costs can be high without coverage (though Ro offers budget-friendly cash-pay options for Zepbound). Your provider can help you navigate both the clinical fit and the practical considerations.
Tirzepatide is not appropriate for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN-2). Certain other medications and health conditions may also affect eligibility.
Side effects and safety warnings
Tirzepatide’s most common side effects are typically temporary and digestion-related, like nausea. However, it can cause more serious effects.
In rare cases, it may lead to inflammation of the pancreas (pancreatitis). Seek emergency medical attention if you have severe stomach pain that won’t go away, with or without nausea or vomiting, especially if the pain spreads to your back. If pancreatitis is confirmed, you will need to stop taking the medication.
Tirzepatide can also cause low blood sugar, particularly if taken with insulin or certain other diabetes medications. Symptoms may include dizziness, shakiness, sweating, blurred vision, confusion, headache, or a fast heartbeat. If you suspect low blood sugar, consume a fast-acting sugar source, such as candy or juice, right away, and seek medical attention. You may need to adjust the doses of your medications to prevent hypoglycemia.
Serious allergic reactions are uncommon but possible. Get medical help immediately if you notice swelling of the face, lips, tongue, or throat, trouble breathing or swallowing, severe rash or itching, or fainting.
These are not the only potential side effects you can experience with tirzepatide. The FDA label contains more complete information about safety. When in doubt, don’t hesitate to seek medical attention. If side effects become intolerable, speak to your healthcare provider about your options.
Bottom line: how much weight can you lose on tirzepatide?
Tirzepatide is one of the most effective medications currently available for weight loss. Here's what to keep in mind about how much weight you can lose on tirzepatide:
Weight loss ranges from 15%–21% depending on your dose and whether you have diabetes. In reality, that's roughly 34–48 lbs for someone starting at 230 lbs.
Most people see weight loss within the first few months. In clinical trials, meaningful reductions were happening by week 24, well in advance of the 72-week endpoint.
Lifestyle habits amplify your results: Tirzepatide works best alongside a nutrient-dense, often calorie-restricted diet and regular physical activity. Protein intake and strength training are especially important for preserving muscle mass during weight loss.
Plateaus are normal and expected: About 90% of people on tirzepatide reach a weight plateau by week 72. This doesn't mean the medication has stopped working; it means your body has found a new equilibrium.
If you're considering tirzepatide for weight loss, Ro can connect you with a licensed healthcare provider who can evaluate whether it's the right fit for you, guide you through treatment safely, and support you every step of the way.
Frequently asked questions (FAQs)
How much weight will I lose in the first month on tirzepatide?
Weight loss in the first month is typically modest. During weeks 1–4, you're on the starting dose of 2.5 mg weekly, which is primarily to help your body tolerate the dose rather than produce noticeable medical effects.
More significant results typically come as the dose increases over the following weeks and months.
How much weight will I lose on Zepbound?
How much weight you'll lose on Zepbound depends on your dose, starting weight, medication adherence, and lifestyle habits. But clinical data shows the average weight loss on tirzepatide across all doses for those without type 2 diabetes is between about 15% and 21% of body weight at 72 weeks.
How long does it take to lose 20 pounds on tirzepatide?
How long it takes to lose 20 pounds on tirzepatide depends on your starting weight, dose, medication adherence, and lifestyle habits.
For someone starting at 230 lbs, for example, losing 20 lbs represents about a 9% reduction, which is a milestone that many people in the SURMOUNT-1 trial reached within the first few months of being on a higher dose.
Keep in mind that tirzepatide starts at a low dose (2.5 mg) and is gradually increased over about 4 to 5 months, so the pace of weight loss picks up as your dose increases.
How much weight can you lose in 3 months on tirzepatide?
If you’re on tirzepatide, you can lose a significant amount of weight in 3 months. Based on research’s weight loss trends, many people lose roughly 5%–10% of their body weight in that timeframe, particularly as their dosage increases.
Does everyone lose weight on tirzepatide?
Yes, most people lose weight on tirzepatide. In SURMOUNT-1 trial, about 85%–91% of people taking tirzepatide lost at least 5% of their body weight by week 72, compared with 35% on placebo.
If you're not seeing results after several months on an adequate dose, it's worth discussing with your healthcare provider.
What happens if I stop taking tirzepatide after losing weight?
If you stop taking tirzepatide after losing weight, you tend to gain a significant amount of weight back. Data from the SURMOUNT-4 trial found that 82.5% of people who stopped tirzepatide regained at least 25% of their lost weight within one year.
Along with the weight, many of the cardiometabolic improvements in blood pressure, blood sugar, and cholesterol also reversed.
How does tirzepatide compare to semaglutide for weight loss?
Tirzepatide produces greater average weight loss than semaglutide. A comparison found that at 72 weeks, people taking tirzepatide lost an average of 20.2% of body weight, while those taking semaglutide lost 13.7%. Safety profiles were similar.
That said, the best medication for you depends on your health history and goals. It’s a decision best made with the support of a healthcare provider.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
References
Aronne, L. J., Horn, D. B., le Roux, C. W., et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England Journal of Medicine, 393(1), 26–36. doi: 10.1056/NEJMoa2416394. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40353578/
Dahl, D., Onishi, Y., Norwood, P., et al. (2024). Tirzepatide. StatPearls. Retrieved on Feb. 23, 2026 from https://www.ncbi.nlm.nih.gov/books/NBK585056
Galindo, R. J., Cheng, A. Y. Y., Longuet, C., et al (2026). Insights into the Mechanism of Action of Tirzepatide: A Narrative Review. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, 17(1), 19–40. doi: 10.1007/s13300-025-01804-w. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12847476/
Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England), 402(10402), 613–626. doi: 10.1016/S0140-6736(23)01200-X. Retrieved from https://pubmed.ncbi.nlm.nih.gov/37385275
Gastaldelli, A., Cusi, K., Fernández Landó, L., et al. (2022). Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. The Lancet. Diabetes & Endocrinology, 10(6), 393–406. doi: 10.1016/S2213-8587(22)00070-5. Retrieved from https://pubmed.ncbi.nlm.nih.gov/35468325/
Horn, D. B., Kahan, S., Batterham, R. L., et al. (2025). Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity, 15(3), e12734. doi: 10.1111/cob.12734. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12096058/
Horn, D. B., Linetzky, B., Davies, M. J., et al. (2026). Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Internal Medicine, 186(2), 157–167. doi: 10.1001/jamainternmed.2025.6112. Retrieved from https://pubmed.ncbi.nlm.nih.gov/41284285/
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 387(3), 205–216. doi: 10.1056/NEJMoa2206038. Retrieved from https://pubmed.ncbi.nlm.nih.gov/35658024/
Liu, X., Lu, C. A., Shih, Y. T., et al. (2025). Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. JAMA Network Open, 8(8), e2529842. doi: 10.1001/jamanetworkopen.2025.29842. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12397888/
Mozaffarian, D., Agarwal, M., Aggarwal, M., et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring, Md.), 33(8), 1475–1503. doi: 10.1002/oby.24336. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12304835/
Samms, R. J., Christe, M. E., Ruan, X., et al. (2019). The dual GIP and GLP-1 receptor agonist tirzepatide regulates lipid and carbohydrate metabolism through GIPR in adipose tissue. Diabetes, 68(Supplement 1), 1009–P. doi: 10.2337/db19-1009-P. Retrieved from https://diabetesjournals.org/diabetes/article/68/Supplement_1/1009-P/58765/1009-P-The-Dual-GIP-and-GLP-1-Receptor-Agonist
Qin, W., Yang, J., Ni, Y., et al. (2024). Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine, 86(1), 70–84. doi: 10.1007/s12020-024-03896-z. Retrieved from https://pubmed.ncbi.nlm.nih.gov/38850440/
Qiu, Y., Fernández-García, B., Lehmann, H. I., et al. (2023). Exercise sustains the hallmarks of health. Journal of Sport and Health Science, 12(1), 8–35. doi: 10.1016/j.jshs.2022.10.003. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9923435/
U.S. Food and Drug Administration (FDA). (2026). Highlights of prescribing information: Mounjaro (tirzepatide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf
U.S. Food and Drug Administration (FDA). (2026). Highlights of prescribing information: Zepbound (tirzepatide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf














